路透2月11日 - 艾伯维ABBV.N公司周三起诉美国卫生与公众服务部，质疑美国医疗保险与医疗补助服务中心（Centers for Medicare & Medicaid Services）根据《2022年联邦通胀削减法》（Inflation Reduction Act of 2022）制定的处方药价格控制政策选择肉毒杆菌毒素（Botox）的决定。
诉讼是在华盛顿特区联邦法院提起的。该诉讼还将 CMS 及其管理者 Mehmet Oz 列为被告。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.